Korea Arlico PharmLtd Valuation
Is A260660 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A260660 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate A260660's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A260660's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A260660?
Other financial metrics that can be useful for relative valuation.
| What is A260660's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | n/a |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.5x |
| Enterprise Value/EBITDA | -17.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does A260660's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.6x | ||
A007370 Jin Yang Pharmaceutical | 0.6x | n/a | ₩66.9b |
A017180 MYUNGMOON PharmLtd | 0.4x | n/a | ₩73.3b |
A014570 Korean Drug | 0.7x | n/a | ₩54.3b |
A000220 Yuyu Pharma | 0.5x | n/a | ₩70.8b |
A260660 Korea Arlico PharmLtd | 0.3x | n/a | ₩58.5b |
Price-To-Sales vs Peers: A260660 is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (0.6x).
Price to Earnings Ratio vs Industry
How does A260660's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?
Price-To-Sales vs Industry: A260660 is good value based on its Price-To-Sales Ratio (0.3x) compared to the KR Pharmaceuticals industry average (0.8x).
Price to Sales Ratio vs Fair Ratio
What is A260660's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.3x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate A260660's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.